The Vantage Point
Why This, Why Now?
Three patterns explain most of what looks, from the outside, like a uniquely Canadian problem with funding or talent. None of them are unique to Canada, and none of them are new — they're well-documented in behavioral science and organizational psychology, including Geert Hofstede's research on national "uncertainty avoidance," one of the most cited frameworks in organizational psychology. What's specific to this work is applying them, rigorously, to where Canadian health innovation actually breaks down.
Inertia
Behavioral economists call it status quo bias — the well-documented tendency to default to no action at all, even when the cost of acting is trivially small and the benefit of changing is clearly visible. It doesn't require fear or malice. It simply requires that nothing pulls hard enough against the existing pattern to overcome the friction of changing it.
In Canadian healthcare and life sciences, this pattern is everywhere and hiding in plain sight. Canadian hospitals still send referrals and lab results by fax machine — not because fax is secure, accurate, or efficient, but because every clinician already knows how to use it and changing would require coordinating a workflow shift nobody has been assigned to own. Electronic health record systems, where they exist, are routinely underused — physicians document around them rather than in them because the system was implemented without genuine workflow integration. And formularies — the lists of drugs hospitals and insurers will actually cover — move with extraordinary slowness even when newer therapies demonstrate clear clinical advantage, because the burden of proof required to displace an existing standard of care is vastly higher than the burden required to keep it in place.
None of these are decisions made by careless people. They are the entirely predictable output of a system where inaction is invisible and action requires effort, coordination, and someone willing to absorb the friction of being the one who pushed for change.
Diffusion of Responsibility
Social psychologists have studied this since the 1960s, when Latané and Darley first documented what became known as the bystander effect: the more people who could plausibly act, the less likely any single one of them does, because each assumes someone else will. It isn't apathy. It isn't negligence. It's a predictable consequence of shared but unassigned accountability — and it scales with the complexity of the system it operates in.
In Canadian health innovation, diffusion of responsibility isn't an edge case. It's the default architecture. A genomics startup spends three years in an Ontario incubator, receives federal IRAP funding, passes a MaRS EXCITE real-world evaluation, and clears Health Canada review. And then it stalls — not because it failed, but because nobody in that chain was ever responsible for what happens next. The incubator's mandate ended at commercialization readiness. The funder's mandate ended at milestone disbursement. The regulator's mandate ended at approval. The hospital's procurement committee is waiting for a clinical champion to make the internal case. And the clinical champion is waiting for someone above them to signal that it's safe to push. Everyone did their job. Nobody owns the handoff.
This pattern repeats across every layer of the ecosystem and at every scale. It's why four federal digital policy bills can be introduced in a single parliamentary session — each defensible on its own merits — with apparently no single body responsible for evaluating their cumulative effect on the digital economy they're simultaneously trying to build. It's why a promising diagnostic tool can be validated in one province and spend a decade failing to cross a provincial border, because interprovincial health technology adoption has no named owner anywhere in the system. And it's why organizations invented tools like RACI charts in the first place — because diffusion of responsibility is so predictable, so universal, and so quietly destructive that entire management disciplines exist specifically to counteract it.
The antidote isn't more collaboration. It's named, singular, unambiguous accountability for every critical transition — assigned before the handoff is needed, not after it has already failed.
Risk Aversion
Decision scientists have long documented a fundamental asymmetry in how institutions assign blame. Kahneman and Tversky's Prospect Theory established that the psychological pain of a loss is roughly twice as powerful as the pleasure of an equivalent gain. But the more consequential finding for institutions isn't about gains and losses in the abstract — it's about visibility. The harm caused by a visible action that fails is judged far more harshly than identical harm caused by quiet inaction. A hospital administrator who approves a new diagnostic platform and it underperforms gets called in front of a committee. One who does nothing while patients wait longer than necessary faces no equivalent accountability. The asymmetry isn't accidental. It's baked into how institutions measure performance and distribute blame.
In Canadian healthcare and life sciences, this has calcified into something more specific than ordinary caution — a cultural operating system where the safest-looking choice at every individual decision point is the one least likely to produce a visible failure, regardless of what it costs in aggregate. Regulatory bodies face intense scrutiny for approving treatments that later show side effects, but almost never equivalent scrutiny for the years patients waited while approvals were delayed. Procurement committees require extensive real-world evidence before adopting technologies already standard of care in comparable health systems, because the career risk of approving something that underperforms outweighs the invisible cost of adopting it five years late. What makes this particularly hard to dislodge is that it doesn't feel like risk aversion from the inside. It feels like prudence.
Crucially, this is also a bidirectional force. The same blame-minimization logic that produces paralysis in hospital procurement produces overreach in federal legislation — decisive action taken specifically to avoid being blamed for inaction. The visible output is opposite. The underlying psychology is identical.
Three Decades. Experience From Every Angle.
Natalie Yeadon started her career as a radiation therapist treating cancer patients, spent eighteen years in pharmaceutical marketing and commercialization — including launching breakthrough therapies like Herceptin and IRESSA — and then built, scaled, and sold Impetus Digital, a company she bootstrapped over sixteen years into a platform used by more than 150 global pharmaceutical brands. She holds a Positive Psychology specialization from the University of Pennsylvania and is a candidate in the Council of Canadian Innovators' Innovation Governance Program.
She's now researching and writing Innovation Paralysis, drawing on three decades of direct experience to explain why a country with world-class research, well-funded incubators, and genuine good intentions keeps failing to get its own innovations to the people who need them.
